Table 1.
Baseline clinical characteristics of patients with IgA nephropathy.
| Characteristic | Value, n = 766 |
|---|---|
| Baseline | |
| Male sex | 391 (51.04) |
| Age, y | 38.05 ± 11.75 |
| MAP, mmHg | 94.28 ± 13.66 |
| Serum albumin, g/L | 39.19 ± 6.07 |
| 24 Proteinuria, g/d | 0.99 (0.49–2.05) |
| PCR, g/g | 0.93 (0.49–1.82) |
| ACR, g/g | 0.55(0.29–1.21) |
| eGFR, mL/min/1.73 m2 | 83.70 ± 29.19 |
| BMI (kg/m2) | 22.93 ± 3.30 |
| CKD stages, n (%) | |
| 1 | 354 (46.21) |
| 2 | 219 (28.59) |
| 3 | 172 (22.45) |
| 4 | 21 (2.74) |
| Oxford classification, n (%) | |
| M1 | 111 (14.49) |
| E1 | 52 (6.79) |
| S1 | 457 (59.66) |
| T1–T2 | 91 (11.88) |
| C1–C2 | 289 (37.73) |
| Follow-up and outcome | |
| Follow-up duration, mo | 29.88 (14.65–51.65) |
| 50% eGFR decline, % | 43 (5.61) |
| Kidney failure, % | 37 (4.83) |
| Composite outcome, % | 51 (6.66) |
Values for continuous variables are expressed as mean ± SD or median [interquartile range]; count (percentage) is used for categorical variables. The composite outcome was defined as a 50% eGFR decline or kidney failure.